In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure
News|Podcasts|January 12, 2026
ACT Brief: Trial Competition Slows AI Gains, Rethinking Patient-Level Safety Decisions, and What Separates Real AI Platforms in Clinical Trials
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we look at how growing trial competition is undermining AI-driven efficiency gains, why pharmacovigilance is shifting toward patient-level causal reasoning, and what AI life sciences companies must demonstrate to stand out in a crowded market.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part two of an Applied Clinical Trials interview, Liz Beatty, co-founder and chief strategy officer at Inato,
said AI is already delivering efficiency gains across protocol design, site feasibility, and trial operations, but those gains are increasingly offset by growing trial competition. Beatty noted that sponsors continue to rely on the same small pool of high-profile sites, creating congestion that slows startup and enrollment, and said broader, more diversified site strategies are needed for AI-driven efficiencies to translate into faster trial completion and patient access. - A new contributor article
outlines why pharmacovigilance tools built for population-level signal detection fall short when real-world safety decisions hinge on individual patients. The article argues for structured patient-level causal attribution to assess proportional contributions of multiple risk factors, moving beyond qualitative labels like “possible” or “probable,” and positioning individual-level reasoning as a downstream complement to existing PV systems rather than a replacement. - In a Pharmaceutical Executive interview, Angela Schwab, CEO of Trialynx,
said AI life sciences companies that stand out are those combining deep domain expertise with structured, step-by-step processes rather than generic AI wrappers. Schwab said AI is enabling a new era of clinical trial design by reducing manual protocol development, improving endpoint selection, and lowering failure rates through better upfront planning that reduces patient and site burden without weakening scientific rigor.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
Trending on Applied Clinical Trials Online
1
Closing the Medical Writing Capacity Gap: Why Training Beats Technology
2
How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?
3
What It Would Take to Make Community Trials Accessible and Scalable
4
Measuring What Matters: Realigning Clinical Endpoints with Patient Reality
5